FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 393 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR New Cancer Model Shows Promise in Predicting If Treatment Will Shrink... July 28, 2022 Garbage Men Finally Meet Cancer-Free Toddler After Bonding From Afar August 7, 2019 Patients with Early Stage NSCLC Have a Higher TMB in Comparison... October 9, 2020 A Cancer Revolution comes to Manchester: Patrick’s review November 24, 2021 Load more HOT NEWS FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive... Treating the Whole Person: How Cancer Centers Are Addressing Social Needs Phase II LCMC3 Study of Neoadjuvant Atezolizumab Met Primary Endpoint with... How can we improve LGBTQ+ cancer care? – That Cancer Conversation...
